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Abstract
Different diseases require different immune responses for efficient protection. Thus, prophylactic vaccines should prime the
immune system for the particular type of response needed for protection against a given infectious agent. We have here
tested fusion DNA vaccines which encode proteins that bivalently target influenza hemagglutinins (HA) to different surface
molecules on antigen presenting cells (APC). We demonstrate that targeting to MHC class II molecules predominantly
induced an antibody/Th2 response, whereas targeting to CCR1/3/5 predominantly induced a CD8+/Th1 T cell response. With
respect to antibodies, the polarizing effect was even more pronounced upon intramuscular (i.m) delivery as compared to
intradermal (i.d.) vaccination. Despite these differences in induced immune responses, both vaccines protected against a
viral challenge with influenza H1N1. Substitution of HA with ovalbumin (OVA) demonstrated that polarization of immune
responses, as a consequence of APC targeting specificity, could be extended to other antigens. Taken together, the results
demonstrate that vaccination can be tailor-made to induce a particular phenotype of adaptive immune responses by
specifically targeting different surface molecules on APCs.
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Introduction
The introduction of mass vaccination represents a major
breakthrough for modern medicine. Thus far, most vaccines have
been developed empirically, with the most successful vaccines
being attenuated pathogens mimicking a natural infection[1].
Attenuated vaccines generally induce strong antibody and T cell
responses, and a single immunization is often sufficient for
obtaining life-long protection. However, live vaccines raise several
safety concerns, and alternatives such as inactivated pathogens or
subunit vaccines are often used instead, despite their reduced
immunogenicity.
The effect of subunit vaccines can be increased by adding
adjuvants to vaccine formulations, thereby influencing the
magnitude and phenotype of immune responses. Vaccine formu-
lations with alum, for example, tend to induce Th2 responses[2],
characterized by CD4+ T cells secreting interleukin-4 (IL-4), IL-5,
IL-9 and IL-13 and expression of the transcription factor GATA-
binding protein 3 (GATA-3)[3]. Th2 cells help B cells[4], and
mediate immunoglobulin (Ig) class swiching to IgG1 in mice[5–7].
Vaccine formulations with the adjuvant monophosphoryl lipid A
(MPL), on the other hand, preferentially induce a Th1-like
immune response[8], characterized by CD4+ T cells secreting the
hallmark cytokine interferon c (IFNc), expression of the
transcription factor T-bet[9], and Ig class switching to IgG2a[7].
Immunogenicity of subunit antigens may also be increased by
targeting of antigen to antigen presenting cells (APCs). Such
targeting may be achieved by coupling of antigen to APC-specific
antibodies either chemically[10–13] or genetically[14–26]. For
genetically constructed vaccines, antigens may be targeted by use
of APC-specific complete Ig[15,16,24], APC-specific scFv[20,23],
or APC-specific natural ligands such as TLR ligands or
chemokines[17,22,25], with antigen attached C-terminally.
An interesting issue is whether the specificity of the APC-
targeted vaccine molecule can influence the phenotype of immune
responses. In this respect, it has been shown that targeting of OVA
to different subsets of dendritic cells (DCs) preferentially induce
CD4+ or CD8+ T cells[24], but it is unclear whether this effect is
due to the specificity for particular surface molecules, or to the
surface molecules being expressed on a particular APC. Further-
more, fusion vaccines consisting of chemokines and antigens have
been demonstrated to efficiently cross-present antigens on MHC
class I molecules[21,22]. Efficient activation of Th1 type CD4+
cells and cytotoxic T lymphocytes (CTL) has also been demon-
strated following targeting to TLR7/8[19]. Improved humoral
immunity has been demonstrated following targeting of vaccines
to TLR5[26], and antigen fused to CTLA4 has been shown to
increase IgG1 responses[15]. The mechanisms behind efficient
induction of either cellular or humoral immunity, or both, have yet
to be elucidated.
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We have previously developed Ig-based homodimeric fusion
vaccine proteins where each monomer consists of a targeting unit,
a dimerization unit and an idiotypic (Id) scFv antigenic unit from
malignant B cells[20]. Targeting of such vaccine molecules to
MHC class II molecules[20], CD40[23] and chemokine recep-
tors[22,25] increased protective anti-Id immune responses against
myelomas and B cell lymphomas. However, it has not been tested
whether the different APC-specificities of the targeting units
induce different types of immune responses. To investigate this, we
have here compared two different targeting units (anti-MHC II
and MIP-1a) for their ability to induce protective B and T cell
responses against influenza hemagglutinin (HA). We demonstrate
that while MHC class II targeting primarily induces antibody/Th2
immunity to HA, targeting to chemokine receptors predominantly
results in CD8+/Th1 cell mediated immunity. The observed
polarization is extendable to other antigens, as the same trends
were observed when vaccinating with targeted OVA antigen. To
our knowledge, the APC-receptor dependent immune polarization
to Th1 or Th2 has previously not been investigated. The observed
differences in elicited immune phenotypes can be exploited to
construct vaccines tailor-made for inducing the desired immune
response against a given pathogen.
Materials and Methods
Cloning of vaccine constructs
Vaccine molecules were constructed by inserting HA (aa 18–
541) from influenza A/PR/8/34 (H1N1) or ovalbumin (OVA)
into the cloning sites of the previously described pLNOH2 CMV-
based vector[20,22,27]. HA was picked up from the plasmid
HAwt-pCMV (kind gift from Harald von Boehmer) by primers
that had been designed with fixed restriction sites for SfiI on the 59
and 39 ends: HA1859; gag gcc tcg gtg gcc tgg aca caa tat gta tag gct
acc and HA54139: gga tcc ggc cct gca ggc ctc aca gtg aac tgg cga
cag. The OVA gene was bought from GenScript with flanking SfiI
sites. A vector encoding only HA (aa 18–541) was prepared by first
mutating internal HA BsmI sites (silent mutations), and then
moving the construct into the pLNOH2 vector (primer with fixed
restriction site for BsmI in the 59 end: ggt gtg cat tcg aca caa tat gta
tag gct acc a, and the 39 end primer described above)[27].
Characterization of fusion vaccine proteins
DNA plasmids encoding the different vaccine proteins were
transfected into HEK293E cells, as previously described[27]. Prior
to assaying, the harvested supernatants were centrifuged at 13
000 rpm for 4 min. For Western blotting, vaccine proteins were
run on a Novex 4–12% Tris-Glycine gel (Invitrogen) together with
a SeeBlue Plus2 Prestained Standard (LC5925, Invitrogen),
blotted (Immun-Blot PVDF membrane, 162–0177, BioRad) and
incubated with a biotinylated anti-HA antibody (H36-4-52, kind
gift from Siegfried Weiss)[28] and Streptavidin-HRP (RPN1231V,
GE Healthcare), or anti-OVA (ab17293, Abcam) and anti-mouse
IgG-HRP (1030-05, Southern Biotech). The membrane was
developed with the ECL Western Blotting analysis system
(RPN2109, GE Healthcare) and analysed on a Kodak Image
station 200R with Molecular Imaging Software v 4.0.5.
Harvested supernatants were also analysed in triplicates in
Sandwich ELISAs using 2 mg/ml of mouse anti-human IgG (CH3
domain) mAb MCA878G (AbD Serotec) as coat. Detection was
performed with 1 mg/ml of biotinylated anti-HA mAb or
biotinylated anti-human IgG (B3773, Sigma) and Strep-alkaline
phosphatase (GE Healthcare). Plates were developed using
Phosphatase substrate (P4744-10G, Sigma Aldrich) dissolved in
substrate buffer, and read with a Tecan reader using the Magellan
v5.03 program.
The chemotactic integrity of MIP-1a-HA and MIP-1a(C11S)-
HA was assessed in vitro, as previously described[25], by
quantifying Esb/MP cell migration across a 5 mm pore polycar-
bonate membrane in response to the titrated presence of vaccine
proteins or a positive control (recombinant LD78b, Peprotech).
Results from duplicate samples (mean) are presented as chemo-
tactic index, defined as the fold increase of cells migrating in the
presence of chemotactic factors over the spontaneous cell
migration (i.e. in the presence of medium alone).
FACS
MHCII I-Ed-transfected L cell fibroblasts (CA36.2.1) were
FccR-blocked by incubation with 30% heat aggregated rat serum
and 0,1 mg/ml 2.4G2 mAb, and then successively stained with
affinity-purified vaccine proteins (10 mg/ml), biotinylated anti-HA
antibody (H36-4-52, 1 mg/ml) and Streptavidin-PE (1 mg/ml)
(554061, PharMingen). Cells were fixed with 2% paraformalde-
hyde, and analysed on a FACS Calibur flow cytometer (BD
biosciences). Splenocytes from BALB/c mice were blocked and
stained with vaccine proteins as above, but here the staining
solution also contained FITC-conjugated anti-CD3 (1535-02,
Southern Biotech) and APC-conjugated anti-CD11b (550993, BD
Pharmingen) antibodies. Splenocytes were analysed on a LSRI
flow cytometer (Becton Dickinson), and data analysed with the
FlowJo software (Version 7.6).
Detection of serum anti-HA or anti-OVA antibodies
Sandwich ELISAs were performed with either inactivated A/
PR/8/34 (H1N1) (PR8) virus (Charles River) (1:1600 in PBS) or
OVA protein (A5503, Sigma) (2 mg/ml) as coat, and detected with
biotinylated anti-IgG (A2429, Sigma Aldrich), anti-IgG1a (553599,
BD Pharmingen), anti-IgG2aa (553502, BD Pharmingen), anti-
IgG2b (553393, BD Pharmingen) or anti-IgG3 (406803, BioLe-
gend), as previously described[27]. Hemagglutination-inhibition
(HI) and micro neutralization assays were performed with PR8 as
previously described[27].
Viruses
A/Puerto Rico/8/34 (H1N1) (PR8) (kind gift from Dr. Anna
Germundsson, National Veterinary Institute, Norway), was
propagated by inoculating virus into the allantoic cavity of 10-
day-old embryonated chicken eggs. TCID50 in pooled allantoic
fluid was determined.
Mice
Six to eight week old female BALB/c mice (Taconic, Denmark)
were used. Animals were housed under minimal disease condi-
tions. All animal experiments were approved by the National
Committee for Animal Experiments (Oslo, Norway).
Vaccination and viral challenge
Mice (n= 6/group) were anaesthetized (Hypnorm/Dormicum:
0,05 ml working solution per 10g s.c.) and shaved in the lower
back region. Twentyfive ml of plasmids (purified from Endofree
Qiagen kit (Qiagen)) dissolved in NaCl (a total of 25 mg DNA),
were injected intradermally on each flank of the mouse,
immediately followed by skin electroporation (EP) with DermaVax
(Cellectis).
For viral challenge, anaesthetized mice received 5xLD50 of PR8
in 10 ml per nostril, as previously described[27]. Following viral
challenge, mice were monitored for weight loss. The endpoint was
APC Surface Specificity and Immune Polarization
PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e80008
a 20% weight reduction, as decided by the National Committee
for Animal Experiments.
Quantitative PCR
Quantitative RT-PCR was performed as previously de-
scribed[27]. Briefly, mice were nasally flushed with 1 ml PBS/
BSA (2%), and RNA extracted from 250 ml of the nasal wash using
NucliSensH easyMagTM (Biome`rieux). Quantitative RT-PCR was
performed with samples in triplicates, and with the following
program using a Stratagene RealTime machine (Qiagen OneStep
RT-PCR kit): 50uC (30 min), 95uC (2 min), followed by 45 cycles:
95uC (15 sec), 55uC (30 sec).
ELISpot assay
ELISpot assays were performed as previously described[27].
Briefly, multiscreen HTS plates (Millipore) were coated with
12 mg/ml anti-mouse IFNc (AN18)[29] or anti-mouse IL-
4(11B11). Following blocking, single cell suspensions were
prepared individually from spleens of vaccinated mice (n = 6/
group), and stimulated with either class II restricted HA peptides
(HNTNGVTAACSHEG or SVSSFERFEIFPK), a class I restrict-
ed HA peptide (IYSTVASSL) (0.8 mg/ml) (ProImmune), a control
peptide (GYKDGNEYI), OVA (Sigma) or inactivated PR8
(Charles River). IFNc or IL-4 producing cells were detected by
biotinylated anti-mouse IFNc (1 mg/ml) (XMG1.2, Pharmingen)
or biotinylated anti-mouse IL-4 (1 mg/ml) (554390 BD Pharmin-
gen) and Streptavidine alkaline phosphatase (1:3000) (GE
Healthcare).
Interferon-c ELISA
Single cell suspensions were prepared from spleens of vaccinat-
ed mice (n = 6/group), and stimulated with either class II restricted
HA peptides (HNTNGVTAACSHEG and SVSSFERFEIFPK,
1:1), a class I restricted HA peptide (IYSTVASSL) (ProImmune),
inactivated PR8 (Charles River) (2 mg/ml) or medium alone.
Supernatants were examined in Sandwich ELISAs with anti-IFNc
mAb (AN18) as coat, and with biotinylated anti-IFNc (XMG1.2,
Pharmingen) for detection. A standard curve of diluted and
purified IFNc was used to assess the concentration of IFNc in sera.
T cell depletion
Mice were DNA/EP vaccinated once with 25 mg aMHCII-HA,
MIP-1a-HA or NaCl (n = 6/group). From day 12 and until
termination of the experiment, groups of mice vaccinated with
MIP-1a-HA were injected every other day i.p. with 400 mg of
either purified anti-CD4 (GK1.5, ATCC)[30], or anti-CD8
(TIB105, ATCC)[31], or both, or control mAbs (SRF8-B6 and
Y13-238). The mice vaccinated with aMHCII-HA were, every
other day from day 12, injected i.p. with 400 mg of anti-CD4 and
anti-CD8. On day 14, mice were challenged with PR8 and
monitored for weight loss.
Statistical analyses
Statistical analyses of antibody responses in sera were performed
using one way Anova and Bonferroni’s multiple comparison test
with the Graphpad Prism software (GraphPad Software Inc.
version 5). All other analyses were performed using the nonpara-
metric Mann-Whitney test (one-tailed value) with Graphpad Prism
software.
Results
Fusion gene cloning and functional characterization of
vaccine fusion proteins
Amino acids 18–541 from influenza HA (A/PR/8/34 (H1N1))
(PR8) were cloned into previously described plasmids that either
encoded a scFv against mouse MHC class II (I-Ed)[20] (aMHCII-
HA)[27] or the chemokine MIP-1a[22] (MIP-1a-HA) as targeting
units (Fig.1a). In non-targeted counterparts, the targeting units
were replaced by either a scFv against the hapten NIP[20] (aNIP-
HA) or a mutated version of MIP-1a abolishing chemotactic
properties[22] [MIP-1a(C11S)-HA]. We also prepared a plasmid
encoding only HA (aa 18–541) in order to evaluate the induced
immune response in the absence of the bivalent fusion protein
structures[27].
DNA plasmids were transfected into HEK293E cells for
examinations of proper structure and function of the different
vaccine fusion proteins. Western blotting of supernatants demon-
strated bands with the predicted sizes (Fig.1b), whereas ELISAs
confirmed secretion of vaccine fusion proteins (Fig.1c). The
vaccine proteins were for the most part covalently dimerized,
but low amounts of monomers were also found (Fig.1b). The
aMHC class II targeting unit was proven functional by assessment
of protein binding to MHCII I-Ed-transfected L-cell fibroblasts
(Fig.1d) and BALB/c CD11b+ splenocytes (Fig.1f)[27]. Intact
functionality of the MIP-1a encoding vaccine was demonstrated in
a chemotactic assay (Fig.1e) and by binding to BALB/c CD11b+
splenocytes (Fig.1g).
Targeted DNA vaccination increases immune responses
following intramuscular delivery
BALB/c mice were vaccinated once by intramuscular (i.m.)
injection of DNA vaccines immediately followed by electropora-
tion to enhance DNA uptake. Sera obtained at day 7, 14 and 21
after vaccination with aMHCII-HA showed large increases in
levels of total IgG, IgG1 and IgG2a in ELISA against PR8 (Fig.2a-
c). By comparison, vaccinations with MIP-1a-HA and non-
targeted controls induced only minor amounts of antibodies.
For assessment of T cell responses, spleen cells harvested at day
21 were stimulated with either MHC class II restricted HA
peptides (SVSSFERFEIFPK or HNTNGVTAACSHEG), a class I
restricted HA peptide (IYSTVASSL)[32–34], or a control peptide
(GYKDGNEYI). EliSpot analysis demonstrated significantly
increased frequencies of interferon gamma (IFNc)-secreting cells
after a single vaccination with the APC targeted vaccines, with
MIP-1a-HA being particularly effective following stimulation with
the class I peptide IYSTVASSL (p,0,0043 as compared to
aMHCII-HA) (Fig.2d-f).
Vaccination with aMHCII-HA increases humoral
responses following intradermal delivery
Evaluation of DNA vaccines in preclinical models is often
performed with i.m. delivery of DNA in combination with
electroporation. However, intradermal (i.d) delivery may be
clinically more tolerable since skin is easier accessible than muscle,
and shorter needles are needed[35]. Furthermore, skin is rich in
APCs, such as Lagerhans cells and dermal dendritic cells[36].
Therefore, we did in further experiments employ i.d. vaccination.
BALB/c mice were vaccinated once i.d. with the DNA plasmids
described above in combination with electroporation, and serum
antibodies against PR8 were measured in ELISA. aMHCII-HA
rapidly induced high and long-lasting titers of IgG1 and IgG2a,
whereas the smaller increases of IgG2b and IgG3 declined to just
APC Surface Specificity and Immune Polarization
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above baseline within 50 days (Fig.3a-e). The increases in ELISA
antibody titers following vaccination with aMHCII-HA were
matched by increased hemagglutination inhibition (HI) and micro
neutralizing titers (Fig.3f,g). In contrast, a single vaccination with
MIP-1a-HA failed to increase antibody titers in ELISA beyond
that observed for non-targeting controls, and hardly any
antibodies were detected in the HI- and microneutralization
assays. Immunization with HA alone failed to induce anti-HA
antibodies in any of the assays.
To assess the effect of repeated immunizations, mice were
vaccinated twice with a 50-days interval. Sera were collected at
various timepoints and assayed against PR8 in ELISA. Results
demonstrated that the boost with aMHCII-HA further enhanced
both IgG1 and IgG2a titers (Fig.3h,i). By comparison, the boost
with MIP-1a-HA failed to increase IgG1 levels beyond that
observed for aNIP-HA (Fig.3h). In striking contrast, the MIP-1a-
HA boost increased serum levels of IgG2a titers to levels
comparable to that of aMHCII-HA from about day 70 to 120,
after which a decline back to background levels was seen (Fig.3i).
Repeated immunizations with HA alone induced antibody titers
comparable to the non-targeted control aNIP-HA.
Figure 1. Characterization of fusion vaccine proteins. a) Schematic overview of homodimeric vaccine proteins. The fusion proteins consists of
HA antigen connected to a targeting unit via a shortened Ig hinge and a dimerizing human c3 CH3 domain and Ig hinge. As targeting units we used a
scFv directed against the MHC class II molecule I-Ed (aMHCII-HA), or the mouse chemokine MIP-1a (MIP-1a-HA). For non-targeted controls, a scFv
directed against the hapten NIP (aNIP-HA), or a mutated MIP-1a (MIP-1a(C11S)-HA), replaced functional targeting units. b) Supernatants of
transfected 293E cells were examined by Western blotting with anti-HA mAb under reducing (-ME) or non-reducing (+ME) conditions. Vaccine
proteins are indicated below lanes, and MW by arrows. c) Binding of vaccine proteins to anti-CH3 mAb in Sandwich ELISA, followed by detection with
an anti-HA mAb. d) Binding of vaccine proteins to MHCII I-Ed-transfected L cell fibroblasts. Vaccine proteins were detected by anti-HA mAb. e)
Supernatants of 293E cells transfected with MIP-1a-HA or the mutated counterpart (C11S) were examined for chemotaxis. Recombinant human MIP-
1a(rLD78b) was included as positive control. Chemotactic index is shown. f, g) Binding of vaccine proteins to CD11b+ BALB/c splenocytes.
doi:10.1371/journal.pone.0080008.g001
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Targeting of HA to either CCR1/3/5 or MHCII induces
different T cell phenotypes
Splenocytes harvested 14 days after one i.d. vaccination were
stimulated in vitro with either class II restricted HA peptides
(SVSSFERFEIFPK or HNTNGVTAACSHEG), a class I restrict-
ed HA peptide (IYSTVASSL), or a control peptide (GYKDG-
NEYI). EliSpot analysis of the relative amounts of cells secreting
IFNc showed that targeting of HA to either MHCII or CCR1/3/
5 resulted in increased T cell activation as compared to the non-
targeted controls (Fig.4a). However, IFNc-secretion was particu-
larly enhanced following vaccination with MIP-1a-HA, and
especially after stimulation with the class I restricted peptide. In
a separate experiment, splenocytes from vaccinated mice were
stimulated in vitro with the above peptides and the levels of secreted
cytokines assessed in ELISA (Fig.4c-f). This experiment confirmed
a strong increase in IFNc secretion following vaccination with
MIP-1a-HA, as compared to aMHCII-HA and non-targeted
controls.
An examination of the relative numbers of interleukin-4 (IL-4)-
producing cells gave the opposite result. Thus, EliSpot analysis of
splenocytes collected 14 days after vaccination and stimulated with
either of the class II restricted HA peptides, demonstrated
increased IL-4 production after vaccination with aMHCII-HA
(p,0,05, compared to MIP-1a-HA) (Fig.4b). Vaccination with
MIP-1a-HA did not elicit IL4-producing cells at all. Taken
together, these results indicate that targeting with MIP-1a induces
a Th1-like response, whereas targeting to MHC class II molecules
predominantly induces a Th2-like response.
Both CCR1,3,5- and MHCII-targeted vaccines protect
against influenza
BALB/c mice were vaccinated once i.d. with DNA/EP and
challenged with influenza virus A/PR/8/34 (H1N1) (PR8) 14 days
later. Mice vaccinated with aNIP-HA or NaCl rapidly lost weight,
and had to be euthanized by day 7. In contrast, mice vaccinated
with aMHCII-HA showed no weight loss or other signs of
discomfort. Vaccination with MIP-1a-HA did not completely
prevent weight loss, and a minor reduction in weight was observed
between days 3 and 5 (Fig.5a). Viral load was examined by RT-
PCR analysis of nasal washes collected from the infected animals
(Fig.5b). Results from day 6 demonstrated that all mice receiving
either aMHCII-HA or MIP-1a-HA had reduced viral titers as
compared to aNIP-HA (p,0,002 and p,0,004, respectively). The
reduction in viral load was more pronounced for aMHCII-HA,
than for MIP-1a-HA.
In a separate experiment, mice were immunized once i.d. and
challenged 9 months later with influenza. Again, vaccination with
aMHCII-HA completely protected mice against weight loss,
whereas mice vaccinated with MIP-1a-HA had a transient and
moderate weight loss (Fig.5c). The long term protection after a
single vaccination was confirmed by RT-PCR of viral load in nasal
washes (Fig.5d).
Figure 2. Targeted DNA fusion vaccines enhance immune responses after intramuscular delivery. Mice were vaccinated once i.m. with
25 mg DNA/electroporation (EP) as indicated (n = 6/group). (a-c) Serum samples were assayed for total IgG (a), IgG1 (b) and IgG2a (c) against PR8 in
ELISA (mean+/-SEM). (d-f) Three weeks after vaccination, splenocytes were harvested and stimulated in vitro with either class II restricted HA peptides
[d, (SVSSFERFEIFPK) or e, (HNTNGVTAACSHEG)], a class I restricted HA peptide [f, (IYSTVASSL)], or a control peptide (GYKDGNEYI). Frequencies of IFNc-
producing cells were evaluated by EliSpot. The control peptide did not elicit responses beyond that observed for NaCl. Horizontal lines indicate
sample means.
doi:10.1371/journal.pone.0080008.g002
APC Surface Specificity and Immune Polarization
PLOS ONE | www.plosone.org 5 November 2013 | Volume 8 | Issue 11 | e80008
Targeting to MHC class II molecules induces antibody-
mediated protection, whereas targeting to CCR1/3/5
induces cellular immunity
To examine T cell contribution to protection, mice were DNA
vaccinated once with MIP-1a-HA and treated from day 12 and on
with injections of depleting mAbs against CD8, CD4, or both. An
additional group was treated with isotype matched mAbs. For
comparison, a group of mice was vaccinated with aMHCII-HA
and treated as above with depleting antibodies against both CD4
and CD8. All mice were challenged with influenza PR8 virus 14
days after vaccination, and monitored for weight loss. Depletion
with mAbs against CD8 and CD4 had no effect on protection
following vaccination with aMHCII-HA, suggesting that the large
amounts of vaccine-induced HA-specific antibodies represent the
main mechanism of protection. By contrast, T cell depletion
abrogated the protection induced by vaccination with MIP-1a-
HA. CD8+ T cells were absolutely required for protection while
CD4+ T cells had a partial protective effect (Fig5e,f).
Targeting of ovalbumin to MHC class II molecules
increases antibody responses, whereas targeting to
CCR1/3/5 increases T cell activation
To test whether the above results could be extended to another
antigen, HA was exchanged for ovalbumin (OVA) in the antigenic
unit of the homodimeric vaccine constructs. Transfectants secreted
vaccine proteins, but about half of these were monomers
indicating inefficient covalent homodimerization (Fig.6a-b).
BALB/c mice were immunized once i.d., and sera from different
time points were analysed in ELISA for OVA-specific antibodies.
Vaccination with aMHCII-OVA increased antibody responses as
compared to MIP-1a-OVA and aNIP-OVA (Fig.6c-e). The
increase was particularly evident for IgG1 (Fig.6d). T cell
responses in vaccinated mice were examined by EliSpot, and
demonstrated a significant increase in IFNc-secretion following
vaccination with MIP-1a-OVA as compared to aMHCII-OVA
(p,0,002) or aNIP-OVA (p,0,008) (Fig.6f).
Figure 3. Antibodies in sera after intradermal DNA vaccination. (a-g) Mice were immunized once i.d. with 25 mg DNA/EP as indicated (n = 6/
group), and assayed for total IgG (a), IgG1 (b), IgG2a (c), IgG2b (d) and IgG3 (e) against PR8 in ELISA (mean+/-SEM). f) Hemagglutination-inhibition (HI)
titers (mean+/-SEM) in sera. g) Sera from day 14 were assayed in a micro neutralization assay (PR8 virus). Dotted line indicates threshold for positive
neutralization (50%). (h,i) Mice were immunized twice i.d. at days 0 and 50 as indicated by arrows (q), and sera assayed in ELISA against PR8 for
induced IgG1 (h) and IgG2a (i) (mean +/- SEM).
doi:10.1371/journal.pone.0080008.g003
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Discussion
Efficient host responses against intracellular bacteria and viruses
generally require Th1 cells and CD8+ T cells, whereas protection
against extracellular pathogens requires antibodies and Th2 cells.
It is therefore important to develop vaccines that can induce the
particular immune response required to fend off a given pathogen.
Previously, others have demonstrated that Th1/Th2 polarization
of CD4+ T cells can be influenced by differences in vaccine
particle size[37], vaccination with an antigen that has been
conjugated to mannan under reducing or oxidative conditions[38],
or co-delivery of antigens and cytokines in the form of DNA[39].
However, to our knowledge, the target-specific induction of
different immune phenotypes has not been investigated. Herein,
we demonstrate that vaccination with HA can be modified to
preferentially activate Th1 associated cellular responses or
antibodies and Th2-like T cells. Such polarization may be
obtained by targeting of HA antigen to CCR1/3/5 and MHC
class II molecules, respectively. The results were extended to a
different antigen (OVA), indicating that the principle should be
applicable to a variety of pathogens.
The observed polarizing effect may be caused by either (i) the
particular APC surface molecule that was targeted or (ii) the
particular APC that displayed the targeted surface molecules. As
for the first mechanism, signaling through MHC class II
molecules, induced by aMHCII-HA vaccine proteins, could
somehow poise the APC for an ability to direct naive T cells
towards Th2 polarization. Conversely, vaccination with MIP-1a-
HA could induce signaling through CCR1,3,5 that would brace
the APC for an ability to induce Th1 differentiation. As for the
second mechanism, MHC class II molecules are displayed by
dendritic cells, B cells and macrophages[40] whereas CCR1,3,5
are expressed on monocytes, macrophages, dendritic cells,
lymphocytes, NK cells, eosinophils, basophils, platelets, neurons,
microlial cells, fibroblasts and endothelial cells[41]. However,
splenocyte stainings indicated that MIP-1a-HA preferentially
bound CD11b+ cells (Fig.1g, and unpublished material), suggesting
that monocytes and macrophages could be particularly important
mediators of the Th1 dominance observed after CCR1,3,5
targeted vaccination. As for the second mechanism, different
receptors on CD8+ DCs (such as Clec9A, DEC205 and Langerin)
have been demonstrated to exhibit similar potentials for induction
of Th1 and CD8+ immunity[42]. These results indicate that cross-
presenting CD8+ DCs preferentially induce CD8+/Th1 responses
regardless of what surface molecule is targeted on this type of
APC. To assess whether the particular surface molecule is of
Figure 4. T cell activation following intradermal DNA vaccination. Mice were immunized once i.d. with 25 mg DNA/EP as indicated (n = 6/
group). (a, b) Fourteen days after vaccination, splenocytes were harvested and analysed in EliSpot assays for IFNc (a) or IL-4 (b) production following
in vitro stimulation with class II restricted HA peptides (SVSSFERFEIFPK or HNTNGVTAACSHEG), a class I restricted HA peptide (IYSTVASSL), or a control
peptide (GYKDGNEYI) (mean+/-SEM). The dotted lines indicate the highest responses found after stimulation with the control peptide. (c-f) Fifteen
days after a single DNA/EP vaccination, splenocytes were stimulated in vitro with medium alone(c), a 1:1 combination of two class II restricted HA
peptides (SVSSFERFEIFPK and HNTNGVTAACSHEG)(d), a class I restricted HA peptide (IYSTVASSL)(e), or inactivated PR8 virus (f). Supernatants were
analyzed in IFNc-ELISA (mean+/- SEM). In d-f, MIP-1a-HA induced significant IFNc-responses compared to either aNIP-HA, or HA, or NaCl (p,0.05).
doi:10.1371/journal.pone.0080008.g004
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relevance, or if the targeted cell subtype is indeed the determining
factor, further investigations are required. Finally, it should be
emphasized that the surface molecule targeted, and the cell type,
together could influence the outcome in terms of polarization.
The APC-targeted fusion proteins were delivered in the form of
DNA. We have previously shown that such vaccines are enhanced
by two factors working in synergy: (i) an APC-targeted fusion
protein encoded by the DNA and (ii) electroporation (EP) of the
DNA injection site. EP increases transfection efficacy[43,44] and
production of secreted vaccine proteins[20]. Furthermore, EP has
been reported to induce local inflammation, and secretion of Th1-
associated cytokines[45,46] at the site of injection. Despite this,
targeting of fusion proteins MHC class II molecules induced a
skewed Th2 response, indicating that the targeting effect is
dominant over the EP effect for Th polarization. Furthermore, we
here show only minor immune responses after vaccination with
non-targeted controls in muscle, demonstrating that the vaccine-
induced effect was dependent upon APC-targeting even in the
presence of EP.
The polarized induction of dominant Th1 or Th2 immune
responses after vaccination with MIP-1a-HA and aMHCII-HA,
respectively, appeared to be independent of vaccination site, since
a similar polarization was observed for both i.m. and i.d. DNA/EP
vaccination. A striking difference between i.m. and i.d. vaccina-
tion, however, was the almost complete lack of immune responses
in muscle following vaccination with non-targeted vaccines. This
difference was particularly evident for antibody responses. The
reason for the difference was not investigated, but may be related
to a higher density of APC in skin as compared to muscle. The
higher APC density in skin is likely to facilitate improved uptake
and presentation of non-targeted vaccine proteins.
Apart from skewing of T cell responses, the targeted vaccines
increased the magnitude of immune responses as compared to the
non-targeted control versions, both in terms of antibody and T cell
responses. Thus, a single i.d. vaccination with aMHCII-HA
Figure 5. Targeted DNA vaccines protect mice against a lethal challenge with influenza virus. Mice were vaccinated once i.d. with 25 mg
of the indicated DNA vaccines/EP. (a, b) Fourteen days after vaccination, mice were given a lethal challenge with influenza PR8. (a) Weight loss after
challenge (mean weight+/-SEM). (b) Viral load in nasal washes from day 6. Ct-values for individual mice are shown. (c, d) Nine months after a single
immunization, mice were given a lethal challenge with PR8 influenza virus and monitored for weight loss (c) and viral load (day 6) (d). Ct-values for
individual mice are shown. (e, f) Mice immunized once with DNA/EP were from day 12 on injected with depleting antibodies against CD4, CD8, both,
or isotype matched controls. On day 14, mice were challenged with a lethal dose of influenza PR8 virus, and monitored for weight loss (e) and survival
(f).
doi:10.1371/journal.pone.0080008.g005
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enhanced IgG titers as compared to controls. A boost further
increased antibody levels after vaccination with aMHCII-HA,
with IgG1 being particularly enhanced. For MIP-1a-HA, a boost
vaccination was needed to induce high IgG2a titers. As concerns T
cell responses, a single vaccination with aMHCII-HA resulted in a
significant increase of IL-4 secreting Th2 cells as compared to the
non targeted control. Similarly, one vaccination with MIP-1a-HA
increased Th1 responses as compared to non targeted controls.
These results are in general agreement with the finding that
Figure 6. Antibody and T cell responses following vaccination with OVA targeted to MHC class II molecules or CCR1/3/5. (a,b)
Supernatants of 293E cells transfected with the indicated plasmids were tested for secreted proteins in ELISA (a) and examined by Western blotting
with anti-OVA mAb under reducing (+ME) or non-reducing (-ME) conditions (b). Vaccine proteins are indicated below lanes. (c-f) Mice were
immunized once i.d. with 25 mg DNA/EP, as indicated. (c-e) Sera were assayed for total IgG (c), IgG1 (d) or IgG2a (e) against OVA. (f) Splenocytes
collected at day 14 post immunization were stimulated in vitro with OVA protein or controls as indicated, and analyzed by an IFNc EliSpot. *indicates
p,0.008 and **p,0.002.
doi:10.1371/journal.pone.0080008.g006
APC Surface Specificity and Immune Polarization
PLOS ONE | www.plosone.org 9 November 2013 | Volume 8 | Issue 11 | e80008
targeting of antigens to APC is known to enhance the immuno-
genicity of subunit vaccines[10–27].
Antibodies represent a well-established correlate of protection
for influenza[47], but current influenza vaccines need to be
reformulated each year due to antigenic drift rendering last years’
antibodies partly or completely ineffective against the new strain.
The complete absence of disease after influenza virus challenge of
aMHCII-HA vaccinated mice indicates that sterilizing Ab-
mediated immunity was induced. This is consistent also with
strongly reduced viral loads in these animals. Moreover, the high
amounts of neutralizing Abs in the aMHCII-HA-vaccinated mice,
and the fact that depletion of both CD4+ and CD8+ T cells did not
abrogate protection, confirmed that aMHCII-HA induced Ab-
mediated protection.
Following ligation, the chemokine receptor CCR5 is phosphor-
ylated and endocytosed via clathrin-coated vesicles[48]. In
agreement with receptor-mediated endocytosis, chemokine fusion
proteins targeting chemokine receptors have been demonstrated to
stimulate efficient vaccine uptake and presentation of antigenic
peptides both in the context of MHC class I[21] and class II
molecules[18]. The ability of an exogenous vaccine to induce
CD8+ T cell responses, called cross-presentation, is a highly
desirable trait that is important for eradication of virus-infected
cells and tumor cells. The potency of chemokine receptor targeting
in induction of CD8+ T cell responses is supported by previous
studies demonstrating that MIP-1a-idiotypic tumor antigen fusion
proteins are highly efficient at preventing cancer in
mice[17,18,21,22].
T cells can also protect against influenza virus[49], and both
CD4+ and CD8+ T cells can independently confer protection[50–
52]. A single vaccination with MIP-1a-HA induced strong HA-
specific Th1 and CD8+ responses, where CD8+ T cells and CD4+
T cells contributed to protection. The T cell responses were
presumably augmented by simultaneous MHC class I and II
presentation of antigenic HA peptides on targeted APCs[53].
MIP-1a-HA did not prevent the establishment of influenza
infection, as can be inferred from the slight weight decrease
observed after viral challenge, but rather induced cytotoxic T cells
that cleared already infected cells[54]. Furthermore, a single
vaccination conferred protection against influenza that lasted at
least 9 months, possibly indicating an initial CD4+ T cell
contribution that could have facilitated the development of
protective memory CD8+ T cells[55,56]. For influenza vaccina-
tion, the induction of strong T cell responses hold promise for
development of novel vaccines that may confer cross protection
against a wider range of influenza strains.
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